NEJM： 降低宫颈癌疫苗成本

 

Source Information

Dr. Agosti is a senior program officer for infectious diseases in the Global Health Program, Bill and Melinda Gates Foundation, Seattle. Dr. Goldie is a professor of health decision science in the Department of Health Policy and Management, Harvard School of Public Health, Boston.

References

 

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24:Suppl 3:S11-S25. [ISI][Medline]
2. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:Suppl 3:S26-S34. [ISI][Medline]
3. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006;24:Suppl 3:S178-S186. [CrossRef][Medline]
4. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005;89:Suppl 2:S4-S12. [CrossRef][Medline]
5. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168. [Free Full Text]